Callahan Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18.5M Buy
20,163
+1,001
+5% +$1.01M 1.55% 22
2025
Q4
$20.6M Buy
19,162
+468
+3% +$447K 1.69% 15
2025
Q3
$14.3M Buy
18,694
+722
+4% +$537K 1.21% 28
2025
Q2
$14M Buy
17,972
+1,312
+8% +$1.02M 1.26% 28
2025
Q1
$13.8M Buy
16,660
+2,326
+16% +$1.94M 1.31% 28
2024
Q4
$11.1M Sell
14,334
-547
-4% -$453K 1.04% 33
2024
Q3
$13.2M Buy
14,881
+301
+2% +$271K 1.28% 25
2024
Q2
$13.2M Buy
14,580
+2,477
+20% +$1.98M 1.37% 26
2024
Q1
$9.42M Buy
12,103
+1,661
+16% +$1.18M 0.99% 35
2023
Q4
$6.09M Buy
10,442
+2,663
+34% +$1.55M 0.71% 49
2023
Q3
$4.18M Buy
7,779
+6,749
+655% +$3.48M 0.52% 54
2023
Q2
$483K Buy
1,030
+150
+17% +$62.9K 0.06% 108
2023
Q1
$302K Sell
880
-10
-1% -$3.37K 0.04% 123
2022
Q4
$326K Buy
890
+90
+11% +$31.9K 0.04% 121
2022
Q3
$259K Sell
800
-50
-6% -$15.8K 0.04% 131
2022
Q2
$276K Buy
850
+25
+3% +$7.5K 0.04% 132
2022
Q1
$236K Sell
825
-25
-3% -$6.43K 0.03% 140
2021
Q4
$235K Buy
+850
New +$215K 0.03% 141

Other funds holding LLY

Callahan Advisors's LLY Position: Q1 2026 in Review

Callahan Advisors increased its Eli Lilly (LLY) stake by 5.2% in Q1 2026, buying an estimated $1.01M and bringing the position to 20,163 shares worth $18.5M. The position accounts for 1.55% of the portfolio, ranked #22.

Callahan Advisors first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. The position peaked at $20.6M in Q4 2025. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Callahan Advisors held 20,163 shares of Eli Lilly worth $18.5M as of Q1 2026.
  • Callahan Advisors bought 1,001 Eli Lilly shares in Q1 2026, an estimated $1.01M.
  • Eli Lilly made up 1.55% of Callahan Advisors's portfolio in Q1 2026, its #22 holding.
  • Callahan Advisors first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
  • Callahan Advisors's Eli Lilly position peaked at $20.6M in Q4 2025.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Callahan Advisors's 13F filing for Q1 2026, filed 12 May 2026.